ATE260912T1 - Oxazol ppar antagonisten - Google Patents

Oxazol ppar antagonisten

Info

Publication number: ATE260912T1
Authority: AT; Austria
Prior art keywords: agonist; lxr; propyl; ppar; formula
Prior art date: 1999-09-08

Application number

AT00959913T

Other languages

English (en)

Inventor

Jeffrey Edmond Cobb

Barry George Shearer

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-08

Filing date

2000-09-01

Publication date

2004-03-15

2000-09-01 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2004-03-15 Application granted granted Critical

2004-03-15 Publication of ATE260912T1 publication Critical patent/ATE260912T1/de

Links

102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 3
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 3
239000005557 antagonist Substances 0.000 title abstract 3
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
239000000556 agonist Substances 0.000 abstract 4
102100038495 Bile acid receptor Human genes 0.000 abstract 2
101000603876 Homo sapiens Bile acid receptor Proteins 0.000 abstract 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
101150095442 Nr1h2 gene Proteins 0.000 abstract 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
230000004913 activation Effects 0.000 abstract 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
102000004311 liver X receptors Human genes 0.000 abstract 2
108090000865 liver X receptors Proteins 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
102000005962 receptors Human genes 0.000 abstract 2
108020003175 receptors Proteins 0.000 abstract 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 2
102000000536 PPAR gamma Human genes 0.000 abstract 1
108010016731 PPAR gamma Proteins 0.000 abstract 1
229940125388 beta agonist Drugs 0.000 abstract 1
239000002876 beta blocker Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
238000007385 chemical modification Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
238000009510 drug design Methods 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT00959913T 1999-09-08 2000-09-01 Oxazol ppar antagonisten ATE260912T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15276199P	1999-09-08	1999-09-08
US19996900P	2000-04-27	2000-04-27
PCT/US2000/024364 WO2001017994A1 (en)	1999-09-08	2000-09-01	Oxazole ppar antagonists

Publications (1)

Publication Number	Publication Date
ATE260912T1 true ATE260912T1 (de)	2004-03-15

Family

ID=26849844

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00959913T ATE260912T1 (de)	1999-09-08	2000-09-01	Oxazol ppar antagonisten

Country Status (8)

Country	Link
US (1)	US6506781B1 (de)
EP (1)	EP1210345B1 (de)
JP (1)	JP2003508529A (de)
AT (1)	ATE260912T1 (de)
AU (1)	AU7115300A (de)
DE (1)	DE60008763T2 (de)
ES (1)	ES2215719T3 (de)
WO (1)	WO2001017994A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
GB0101933D0 (en) *	2001-01-25	2001-03-07	Astrazeneca Ab	Therapy
AR035533A1 (es)	2001-01-26	2004-06-02	Schering Corp	Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
EP1911462A3 (de)	2001-01-26	2011-11-30	Schering Corporation	Zusammensetzungen enthaltend einen Sterolabsorptionshemmer
IL156445A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1394154A4 (de) *	2001-03-23	2005-05-18	Takeda Pharmaceutical	Fünfgliedriges heterocyclisches alkansäurederivat
DE60237594D1 (de) *	2001-04-25	2010-10-21	Takeda Pharmaceutical	Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
US6967212B2 (en) *	2001-05-30	2005-11-22	Bristol-Myers Squibb Company	Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US20030092736A1 (en) *	2001-05-30	2003-05-15	Cheng Peter T.	Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
HRP20040164A2 (en) *	2001-08-29	2004-10-31	Warner Lambert Co	Oral antidiabetic agents
EP1435946B8 (de)	2001-09-14	2013-12-18	Amgen Inc.	Verknüpfte biaryl-verbindungen
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es)	2001-09-21	2004-06-18	Schering Corp	Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
GB2381866A (en) *	2001-11-12	2003-05-14	Karobio Ab	Assays for liver X receptor (LXR) modulators
US7205321B2 (en)	2001-11-15	2007-04-17	Eli Lilly And Company	Peroxisome proliferator activated receptor alpha agonists
AU2002367060A1 (en)	2001-12-21	2003-07-30	X-Ceptor Therapeutics, Inc.	Heterocyclic modulators of nuclear receptors
US6870466B2 (en) *	2002-04-03	2005-03-22	Hewlett-Packard Development Company, L.P.	Data display system and method for an object traversing a circuit
US6716842B2 (en)	2002-04-05	2004-04-06	Warner-Lambert Company, Llc	Antidiabetic agents
US6790929B2 (en) *	2002-06-12	2004-09-14	General Electric Company	Method for making an aromatic polycarbonate
BR0312503A (pt) *	2002-07-09	2007-06-26	Bristol Myers Squibb Co	derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
US7137963B2 (en) *	2002-08-26	2006-11-21	Flowcardia, Inc.	Ultrasound catheter for disrupting blood vessel obstructions
US7368578B2 (en)	2002-09-10	2008-05-06	Takeda Pharmaceutical Company Limited	Five-membered heterocyclic compounds
WO2004043457A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2007504285A (ja) *	2003-01-17	2007-03-01	メルク　エンド　カムパニー　インコーポレーテッド	Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
US20060258840A1 (en) *	2003-01-22	2006-11-16	Mosley Ralph T	Peroxisome proliferator-activated receptor
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1601668B1 (de)	2003-03-07	2008-08-27	Schering Corporation	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517572C (en)	2003-03-07	2011-12-13	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US6987118B2 (en)	2003-05-21	2006-01-17	Pfizer Inc.	Tetrahydroisoquinoline derivatives as PPAR-alpha activators
NZ550857A (en) *	2004-04-01	2009-12-24	Aventis Pharma Inc	1,3,4-oxadiazol-2-ones as PPAR delta modulators
AU2005230838A1 (en) *	2004-04-01	2005-10-20	Aventis Pharmaceuticals Inc.	1,3,4-oxadiazol-2-ones as PPAR delta
CN100467456C (zh) *	2004-05-24	2009-03-11	北京摩力克科技有限公司	作为hPPARα和/或hPPARγ激活剂的α-哌嗪取代的苯丙酸衍生物
CN100436430C (zh) *	2004-05-24	2008-11-26	北京摩力克科技有限公司	作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
WO2006020830A2 (en) *	2004-08-12	2006-02-23	Amgen Inc.	Bisaryl-sulfonamides
US20070142326A1 (en) *	2004-09-30	2007-06-21	Youe-Kong Shue	Treatment of a condition in a mammal with administration of aminosugar and uses thereof
EP1810689A4 (de) *	2004-10-15	2009-07-22	Mitsubishi Tanabe Pharma Corp	Mittel zur prävention und/oder behandlung von diabetes
WO2006044961A1 (en) *	2004-10-20	2006-04-27	Smithkline Beecham Corporation	Ppar-gamma modulatores
PL371841A1 (pl) *	2004-12-20	2006-06-26	ADAMED Sp.z o.o.	Nowe związki pochodne kwasu 3-fenylopropionowego
PL372332A1 (pl)	2005-01-19	2006-07-24	ADAMED Sp.z o.o.	Nowe związki, pochodne kwasu 3-fenylopropionowego
PL372356A1 (pl)	2005-01-20	2006-07-24	ADAMED Sp.z o.o.	Nowe związki, pochodne kwasu 3-fenylopropionowego
US20100196509A1 (en)	2005-02-28	2010-08-05	Jonathan Braun	Methods for Diagnosis and Treatment of Endometrial Cancer
US8648052B2 (en) *	2005-04-15	2014-02-11	The Regents Of The University Of California	Prevention of chlamydia infection using SIRNA
WO2006113526A2 (en)	2005-04-15	2006-10-26	The Regents Of The University Of California	Prevention of chlamydia infection using a protective antibody
US8318906B2 (en)	2005-04-15	2012-11-27	The Regents Of The University Of California	EMP2 antibodies and their therapeutic uses
JP5911805B2 (ja)	2009-11-20	2016-04-27	ザリージェンツオブザユニバーシティオブカリフォルニア	上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
US20130156720A1 (en)	2010-08-27	2013-06-20	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
DK3043865T3 (da)	2013-09-11	2021-02-01	Univ Claude Bernard Lyon	Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
US20160199364A1 (en) *	2015-01-13	2016-07-14	Creighton University	Seizure treatment compositions and methods
CN106146483A (zh) *	2015-04-23	2016-11-23	上海迪诺医药科技有限公司	杂环类法尼酯衍生物x受体调节剂
WO2018178260A1 (en)	2017-03-30	2018-10-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses

2000
- 2000-09-01 US US10/070,474 patent/US6506781B1/en not_active Expired - Fee Related
- 2000-09-01 WO PCT/US2000/024364 patent/WO2001017994A1/en not_active Ceased
- 2000-09-01 EP EP00959913A patent/EP1210345B1/de not_active Expired - Lifetime
- 2000-09-01 AU AU71153/00A patent/AU7115300A/en not_active Abandoned
- 2000-09-01 AT AT00959913T patent/ATE260912T1/de not_active IP Right Cessation
- 2000-09-01 ES ES00959913T patent/ES2215719T3/es not_active Expired - Lifetime
- 2000-09-01 JP JP2001522217A patent/JP2003508529A/ja not_active Withdrawn
- 2000-09-01 DE DE60008763T patent/DE60008763T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1210345B1 (de)	2004-03-03
AU7115300A (en)	2001-04-10
WO2001017994A1 (en)	2001-03-15
DE60008763T2 (de)	2005-02-10
DE60008763D1 (de)	2004-04-08
JP2003508529A (ja)	2003-03-04
EP1210345A1 (de)	2002-06-05
US6506781B1 (en)	2003-01-14
ES2215719T3 (es)	2004-10-16

Legal Events

Date	Code	Title	Description
2004-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60008763D1 (de)	2004-04-08	Oxazol ppar antagonisten
DK1173433T3 (da)	2006-05-15	Cyanopyrroler som progesteronreceptoragonister
HUP0303339A2 (hu)	2004-01-28	Heteroaril-karbamid neuropeptid Y Y5 receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
ATE401066T1 (de)	2008-08-15	Methoden zur behandlung der essstörungen
NO20003671L (no)	2000-09-18	4-(2-keto-1-benzimidazolinyl)piperidin-forbindelser som orl1- reseptor agonister
MY141559A (en)	2010-05-14	Triazole derivatives as tachykinin receptor antagonists
JP2004532209A5 (de)	2005-12-22
CO5611063A2 (es)	2006-02-28	Pirazolilcarboxanilidas disubstituidas
DE60120748D1 (de)	2006-07-27	3-substituierte oxindolderivate als beta-3-agonisten
ATE213738T1 (de)	2002-03-15	Azaheterocyclische tachykinin rezeptor antagoniste; nk1 und nk2
RU2007121850A (ru)	2008-12-20	Производные фосфонооксихиназолина и их фармацевтическое применение
BR9508292A (pt)	1997-12-23	Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos
DE60218703D1 (de)	2007-04-19	(-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
MY146532A (en)	2012-08-15	Thiazole derivative
UA72917C2 (en)	2005-05-16	Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
SE9900274D0 (sv)	1999-01-28	New compound
CO5251427A1 (es)	2003-02-28	Oxazolidinonas que tienen la fucion de sulfoximina
DE60007347D1 (de)	2004-01-29	Isoxazolcarboxamid-derivate als antagonisten des alpha1-adrenergischen rezeptors
NO992226L (no)	1999-05-27	Nye forbindelser for anvendelse som neuro-protektive midler
DK1487424T3 (da)	2007-01-08	4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl)-pyrimidin-2-yl-amino)phenyl-benzamid til behandling af Ang II-medierede sygdomme
NO20014855D0 (no)	2001-10-05	N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
ATE366572T1 (de)	2007-08-15	5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
NO20042257L (no)	2004-06-24	Fremgangsmate for behandling av depresjon med deltareseptoragonistforbindelser
PE20060770A1 (es)	2006-10-03	Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
ATE206419T1 (de)	2001-10-15	N-benzensulfonyl-l-prolinderivate als bradykininrezeptor b2 antagonisten